

Prescription of Antibiotics for Periodontal Disease among Dentists in the Region of Tirana

Besian Abazi^{1*}, Joana Mihani²

¹Albanian University, Faculty of Medical Sciences, Department of Dentistry, Tirana, Albania; ²University of Medicine Tirana, Department of Pharmacy, Tirana, Albania

Abstract

Citation: Abazi B, Mihani J. Prescription of Antibiotics for Periodontal Disease among Dentists in the Region of Tirana. Open Access Maced J Med Sci. 2018 Aug 20; 6(8):1486-1491. https://doi.org/10.3889/oamjms.2018.300

Keywords: Antibiotics; Dental prescriptions; Periodontitis

***Correspondence:** Besian Abazi. Albanian University, Faculty of Medical Sciences, Department of Dentistry, Tirana, Albania. E-mail: Abazi.besian@gmail.com

Received: 10-Apr-2018; **Revised:** 07-Jun-2018; **Accepted:** 04-Jul-2018; **Online first:** 15-Aug-2018

Copyright: © 2018 Besian Abazi, Joana Mihani. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)

Funding: This research did not receive any financial support

Competing Interests: The authors have declared that no competing interests exist

BACKGROUND: Periodontal disease has been and will be a challenge for dentists in the entirety of oral pathologies. To date, there is no data regarding the prescription of antibiotics for periodontitis in the district of Tirana.

AIM: Evaluate aspects related to the pattern of prescription of antibiotics among dentists in Tirana region for periodontitis.

METHODS: Prescriptions from dental practitioners were collected from 25 pharmacies, randomly selected. The only prescription containing a diagnosis of periodontitis, with at least one antibiotic given, was included in the study. Data analysis was done with SPSS 20.

RESULTS: Out of 1159 initial prescriptions, only 314 met the selection criteria. The average age of patients was 39.91 ± 15.21 years. Mean duration of therapies was 5.57 ± 1.5 days. The most common form of prescription was one broad-spectrum antibiotic (74.5%), combined antibiotics therapy (22.3%) and narrow-spectrum antibiotic (3.2%). Combined antibiotics involved the use of Metronidazole with Amoxicillin (12.1%) and Metronidazole with Spiramycin (10.2%). Significant differences in the patterns of prescription were identified in relation with patient age and therapy duration ($P < 0.05$). No statistical difference was found in the patient's gender and the typology of the therapy ($P > 0.05$).

CONCLUSIONS: Our study shows prescription characteristics of antibiotics for periodontal disease by dentists in Tirana for the first time. Amoxycillin is the most prescribed antibiotic, followed by amoxicillin with clavulanic acid. We found variation in dosage, frequency and duration for all antibiotics used, and perceptible discrepancies between observed and recommended practice. Guidelines on rational antibiotic use are needed for dental practitioners in Tirana and the Republic of Albania for better management of periodontitis and resistance prevention.

Introduction

Periodontitis is an inflammatory disease which affects the supporting tissues of the tooth. It constitutes one of the most frequent bacterial infection in adults. There are hundreds of bacterial species associated with this disease, thus making it difficult to achieve a successful specific therapy for periodontitis [1]. Among these the most relevant are *Aggregatibacter actinomycetemcomitans* (A.a.), *Porphyromonas gingivalis* (*P. gingivalis*), *Treponema denticola* (*T. denticola*), *Fusobacterium nucleatum* (*F. nucleatum*) and *Prevotella intermedia* (*P. intermedia*),

[2] [3] [4]. *P. gingivalis* is considered as the main cause of chronic periodontitis, though no less important is the A.a., which is recognised as the leading cause of aggressive periodontitis [2] [5] [6]. Difficulties faced by periodontists lie in the fact that the restoration of normality for the periodontal tissues becomes difficult with time. If left untreated, it can progress into an irreversible situation [7]. There are some procedures and protocols aimed to prevent the progression of the lesion, maintain current levels of periodontal tissues and restore periodontal health. To succeed in these procedures, in addition to manual curettage and periodontal surgery, systemic antibiotic therapy is a key factor [8] [9] [10] [11]. Strong

evidence exists to support benefits of manual curettage to remove supra and subgingival plaque. Hence, without the use of antibiotics, this procedure is unable to eradicate pathogenic bacterial species and thus to maintain gingival levels of adhesion [8] [12] [13]. To support such procedures, except monotherapy with antibiotics, dental practitioners use a combination of antibiotics known as a combined therapy or dual antibiotic therapy [14] [15] [16].

To the best of our knowledge, to date, there is no data regarding the prescription of antibiotics for periodontitis in the region of Tirana.

Materials and Methods

This retrospective drug utilisation study was conducted over a period of 3 months, March-June 2016. It involved prescriptions collected from 25 randomly selected pharmacies in the region of Tirana. We collected prescriptions dispensed by dentists and selection criteria included prescriptions: (a) limited and only for periodontitis in patients ≥18 years old; and (b) with at least one antibiotic prescribed. Prescriptions with other systemic drugs or local medications were excluded from the study.

Collected data were analysed using the statistical software SPSS 20 (IBM, USA). Differences between patterns of prescription, patient's age, gender and treatment duration were compared using One-way ANOVA and Chi-square tests. *P*-values < 0.05 were considered statistically significant.

Results

From 1159 collected prescriptions, only 314 met the selection criteria. The gender ratio was 1:1.12 consisting of 148 Males (47.1%) and 166 Females (52.9%). The average age was 39.91 ± 15.21years (18-81). Mean duration of therapies was 5.57 ± 1.5 days (3-10) (Table 1).

Table 1: Age and therapy duration variables parameters

	Age of patients	Duration of therapy
Mean	39.91	5.57
Median	36.00	5.00
Mode	25	5
Standard deviation	15.21	1.50
Minimum	18	3
Maximum	81	10

Three patterns of antibiotic prescription were observed: (a) 74.5% single therapies with a broad-spectrum antibiotic (BSA), (b) 22.3% combined therapies (CT) consisting in a broad-spectrum

antibiotic and a narrow-spectrum antibiotic and (c) 3.2% narrow-spectrum antibiotic (NSA) (Table 2).

Table 2: Frequency of type of antibiotic therapies

The pattern of antibiotic prescription	Value	%
Broad spectrum	234	74.5
Broad and narrow spectrum combination	70	22.3
Narrow spectrum	10	3.2

Among 234 BSA prescriptions, Amoxicillin is the most prescribed drug (32,5%), followed by Amoxicillin-Clavulanic Acid (22%) and Spiramycin (12.7%). Instead, Erythromycin (4.1%), Azithromycin (1.6%) and Ciprofloxacin (1.6%) are less prescribed drugs. CT involved the use of Amoxicillin with Metronidazole (12.1%) and Spiramycin with Metronidazole (10.2%). Regarding the use of NSA, only Metronidazole was prescribed (Table 3).

Table 3: Percentage of antibiotic prescription and characteristics of therapy duration

Antibiotic	%	Therapy duration (days)			
		Mean	Maximum	Minimum	Mode
Broad spectrum					
Amoxicillin	32.5	5	7	3	5
Amoxicillin with Clavulanic Acid	22	5	7	3	5
Spiramycin	12.7	5	7	3	5
Erythromycin	4.1	5	6	3	5
Ciprofloxacin	1.6	5	7	4	4
Azithromycin	1.6	5	5	5	5
Mixed spectrum					
Metronidazole+Amoxicillin w/Clavulanic Acid	12.1	7	10	6	7
Metronidazole+Spiramycin	10.2	8	10	5	7
Narrow spectrum					
Metronidazole	3.2	6	7	6	6

One-way ANOVA test indicated the statistically significant difference between the three typologies of antibiotic therapy prescribed, patient's age and treatment duration (Table 4).

Table 4: One Way ANOVA test results for patients age and treatment duration about the type of therapy

	Sum of Squares	df	Mean Square	F	Sig.
Age	3106.280	2	1553.140	6.962	0.001
Treatment duration	399.900	2	199.950	201.206	0.000

Post Hoc test demonstrated that the single BSA therapy and CT do not show significant differences in mean patients age, while NS therapy presented significant difference compared with both therapies (Table 5).

Table 5: Multiple comparisons where the dependent variable is patient age

(I) Antibiotic type	(J) Antibiotic type	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
Broad spectrum antibiotic	Combined therapy	1.469	2.035	.751	-3.32	6.26
	Metronidazole	17.912	4.823	.001	6.55	29.27
Combined therapy	Broad spectrum antibiotic	-1.469	2.035	.751	-6.26	3.32
	Metronidazole	16.443	5.049	.004	4.55	28.33
Narrow spectrum antibiotic	Broad spectrum antibiotic	-17.912	4.823	.001	-29.27	-6.55
	Combined therapy	-16.443	5.049	.004	-28.33	-4.55

Data shows that NSA like Metronidazole tends to be prescribed to younger patients with a mean age of 23 years (Figure 1).




Figure 1: Mean patients age

Furthermore, Post Hoc test showed the statistically significant difference between all three types of antibiotic therapies regarding the duration of therapies (Table 6).

Table 6: Multiple comparisons where the dependent variable is therapy duration

(I) Antibiotic type	(J) Antibiotic type	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
Broad spectrum antibiotic	Combined therapy	-2.705 [*]	0.136	0.000	-3.03	-2.39
	Metronidazole	-1.377 [*]	0.322	0.000	-2.14	-0.62
Combined therapy	Broad spectrum antibiotic	2.705 [*]	0.136	0.000	2.39	3.03
	Metronidazole	1.329 [*]	0.337	0.000	.53	2.12
Narrow spectrum antibiotic	Broad spectrum antibiotic	1.377 [*]	0.322	0.000	.62	2.14
	Combined therapy	-1.329 [*]	0.337	0.000	-2.12	-0.53

The single broad-spectrum antibiotic regime has a mean duration of 4.92 days while Metronidazole therapy for 5 days. Dual therapy has the longest regimen, with a mean of 7.63 days (Figure 2).




Figure 2: Mean therapy duration

No statistical difference was found in the patient's gender and the typology of the therapy ($P > 0.05$).

Discussion

This study shows that dentists in the Tirana region tend to prescribe BSA in 74.5% of cases. Amoxicillin alone and its combination with Clavulanic acid are prescribed in more than half of cases (54.5%). Amoxicillin is found to be useful in the management of patients with aggressive periodontitis, in both localised and generalised forms [17] [18]. Also, its combination with Clavulanate potassium shows to incline bacterial resistance. Also, Spiramycin is frequently used. In 12.7% of prescription, it is used alone for the management of periodontal disease. Spiramycin has shown promising results in the treatment of advanced forms of periodontitis, and as an adjunct to thorough scaling and root planning, provides a statistically significant improvement in probing depths for up to 24 weeks when compared with scaling and root planing alone. Furthermore, it produces a significant improvement in attachment level [18] [19] [20] [21].

On the other hand, NSA alone, such as Metronidazole remains a non-primary choice for the pharmacological treatment of periodontal disease, with only 3.2% of prescriptions. Although, the literature shows that Metronidazole has a prominent effect on periodontitis, yet there is scepticism among dentists who are reluctant to prescribe it. However, Metronidazole alone it's not the drug of choice for treating A.a. infections. Instead, it's a combination with other antibiotics shows to be effective against these bacteria [22] [23]. Also, it is effective against anaerobes such as *P. gingivalis* and *P. intermedia* [24]. Studies have suggested that Metronidazole combined with Amoxicillin or Amoxicillin-Clavulanate potassium, it may be with great impact in the management of patients with aggressive periodontitis [23] [25] [26] [27] [28]. In our study, Metronidazole was mostly used in combination with Amoxicillin 12.1% and with Spiramycin in 10.2%. Of the cases.

Clinical research suggests that Ciprofloxacin with Metronidazole is a powerful antibiotic combination against mixed infections. At present, Ciprofloxacin is the only antibiotic in periodontal therapy to which all strains of A.a. are susceptible [29] [30] [31] [32]. Metronidazole targets obligate anaerobes, and Ciprofloxacin targets facultative anaerobes. This type of therapy can be of great benefit for the patients since periodontal infections contain a wide diversity of bacteria, and this scenario makes it mandatory to use more than one antibiotic, either serially or in combination [33] [34] [35] [36] [37]. Nevertheless, data shows that dentists in Tirana region do not use this combination.

The duration of the treatment shows to be a problem itself, with a mean of 5.57 ± 1.5 days. Dentists who prescribe only one antibiotic, prefer a 5-days therapy. In contrast, dentists that have chosen a combination therapy have prescribed it for a longer

time, and this can be the case of chronic resistant periodontitis. Only the CT has a mean duration of 7.63 days. None of the prescriptions had a prolonged therapy for more than ten days. Therapies with BSA, have a mean duration of 4.92 days and a therapy with NSA has a mean duration of 6.3 days. This is a short-term therapy which may pose a risk regarding antibiotic resistance rather than a successful treatment for the disease. This, especially in cases of chronic periodontitis where the presence of periodontal pathogens, specifically A.a., is known to endure in tissues after therapy and re-infect the pocket. Thus, the use of systemic antibiotics was thought to be necessary to eliminate pathogenic bacteria from the tissues [27].

Interpretation of the processed data, not only does show that NSA like Metronidazole have a limited number of prescriptions, but it is more used in young adults. Patients with a generalised form of the disease usually appear to be young, and they present generalised attachment loss and poor antibody response. Therefore, these patients often have a fair, poor, or questionable prognosis, and they need an effective systemic antibiotics therapy. This is in contrast with our findings of NSA use in younger adults.

Evidence shows that there is a lack of knowledge for antibiotic prescription patterns and duration of therapy in dentists in the region of Tirana. The increasing resistance problems of recent years are probably related to the over-or misuse of antibiotics. There is a clear need for the development of prescribing guidelines and educational initiatives to encourage the rational and appropriate use of antibiotics in dentistry, especially periodontal problems. These are issues we found to be present also in other countries [38] [39] [40] [41] [42] [43] [44].

While the use of antibiotics in periodontal treatment will probably always be controversial, the position paper of the American Academy of Periodontology contains valuable guidance for their use, and we would recommend their application in everyday practice by dentists. Following exhaustive literature searches, this paper determined that patients with aggressive periodontitis appear to benefit from the adjunctive use of systemic antibiotics during treatment. Systemic antibiotic therapy helps the manual curettage and improves immune response to eliminate subgingival bacteria, which are not affected by manual therapy [12]. The mechanical curettage without the addition of systemic antibiotics would probably be a failure considering the rapid bacterial colonisation of periodontal pockets [36].

Based on WHO latest report, antimicrobial resistance poses a "global health security threat" to public health [45]. Subsequently, to benefit the most from these therapies, we must limit their use and prescribe the right dosage and duration of therapy to prevent further resistance.

In conclusion, our study shows prescription characteristics of antibiotics for periodontal disease by dentists in Tirana for the first time. Most of the dentist in the district of Tirana, for periodontitis, prescribes only one broad-spectrum antibiotic. Amoxicillin was the most preferable, followed by amoxicillin with clavulanic acid. Metronidazole a narrow spectrum antibiotic is prescribed more in young adults, while combined therapies and broad-spectrum antibiotics tend to be prescribed with the increasing of patient's age. We found variations in dosage and frequency for all the antibiotics used, particularly concerning data exists regarding the short duration of therapies prescribed. Perceptible discrepancies were observed between recommendations and practice. Therefore, these observations highlight the need for dentists to improve antibiotic prescribing practices for periodontal problems. Guidelines on rational antibiotic use are needed for dental practitioners in Tirana and in the Republic of Albania for a better management of periodontitis and resistance prevention.

References

1. Shaikh HFM, Patil SH, Pangam TS, Rathod KV. Polymicrobial synergy and dysbiosis: An overview. *J Indian Soc Periodontol.* 2018; 22(2):101-106. https://doi.org/10.4103/jisp.jisp.385_17 PMID:29769762 PMCID:PMC5939015
2. Shi M, Wei Y, Hu W, Nie Y, Wu X, Lu R. The Subgingival Microbiome of Periodontal Pockets With Different Probing Depths in Chronic and Aggressive Periodontitis: A Pilot Study. *Front Cell Infect Microbiol.* 2018; 8:124. <https://doi.org/10.3389/fcimb.2018.00124> PMID:29765908 PMCID:PMC5938363
3. Feng Z, Weinberg A. Role of bacteria in health and disease of periodontal tissues. *Periodontology* 2000. 2006; 40(1):50-76. <https://doi.org/10.1111/j.1600-0757.2005.00148.x> PMID:16398685
4. Simón-Soro A, Tomás I, Cabrera-Rubio R, Catalan MD, Nyvad B, Mira A. Microbial geography of the oral cavity. *J Dent Res.* 2013; 92(7):616-21. <https://doi.org/10.1177/0022034513488119> PMID:23674263
5. Slots J, Ting M. *Actinobacillus actinomycetemcomitans* and *Porphyromonas gingivalis* in human periodontal disease: occurrence and treatment. *Periodontology* 2000. 1999; 20(1):82-121. <https://doi.org/10.1111/j.1600-0757.1999.tb00159.x> PMID:10522224
6. Van der Velden U. What exactly distinguishes aggressive from chronic periodontitis: is it mainly a difference in the degree of bacterial invasiveness? *Periodontol* 2000. 2017; 75(1):24-44 <https://doi.org/10.1111/prd.12202> PMID:28758297
7. Lang NP, Lindhe J, editors. *Clinical periodontology and implant dentistry*, 2 Volume Set. John Wiley & Sons, 2015.
8. Seiler SJ, Herold WR. The use of systemic antibiotics in the treatment of aggressive periodontal disease. *Gen Dent Periodont.* 2005.
9. Blair FM, Chapple IL. Prescribing for periodontal disease. *Prim Dent J.* 2014; 3(4):38-43. <https://doi.org/10.1308/205016814813877234> PMID:25668374
10. Duffau F, Bensahel JJ, Blanchard P, Cohen R, Descroix V, et al. Agence française de sécurité sanitaire des produits de santé AFSSAPS. Prescription of antibiotics for oral and dental care. *Med Mal Infect.* 2012; 42(5):193-202.

- <https://doi.org/10.1016/j.medmal.2011.12.004> PMID:22503659
11. Mombelli A, Décaillet F, Almaghlouth A, Wick P, Cionca N. Efficient, minimally invasive periodontal therapy. An evidence-based treatment concept. *Schweiz Monatsschr Zahnmed.* 2011; 121(2):145-57. PMID:21344327
 12. The American Academy of Periodontology (position paper), Systemic antibiotics in periodontics. *J Periodontol.* 2004; 75:1553-1565. <https://doi.org/10.1902/jop.2004.75.11.1553>
 13. Kinane DF, Stathopoulou PG, Papapanou PN. Periodontal diseases. *Nat Rev Dis Primers.* 2017; 3:17038. <https://doi.org/10.1038/nrdp.2017.38> PMID:28805207
 14. Herrera D, Alonso B, León R. Antimicrobial therapy in periodontitis: the use of systemic antimicrobials against the subgingival biofilm. *J Clin Periodontol.* 2008; 35:45-66. <https://doi.org/10.1111/j.1600-051X.2008.01260.x> PMID:18724841
 15. Ciancio SG. Systemic medications: Clinical significance in periodontics. *J Clin Periodontol.* 2002; 29(Suppl 2):17-21. <https://doi.org/10.1034/j.1600-051X.29.s2.3.x> PMID:12087965
 16. Rajendra A, Spivakovsky S. Antibiotics in aggressive periodontitis, is there a clinical benefit?. Evidence-based dentistry. 2016; 17(4):100. <https://doi.org/10.1038/sj.ebd.6401197> PMID:27980332
 17. Weinstein L. Antimicrobial agents. The pharmacological basis of therapeutics. 1975:1201-23.
 18. Usin MM, Tabares SM, Menso J, de Albera ER, Sembaj A. Generalized aggressive periodontitis: microbiological composition and clinical parameters in non-surgical therapy. *Acta Odontol Latinoam.* 2016; 29(3):255-261. PMID:28383606
 19. Rams TE, Dujardin S, Sautter JD, Degener JE, Van Winkelhoff AJ. Spiramycin resistance in human periodontitis microbiota. *Anaerobe.* 2011; 17(4):201-5. <https://doi.org/10.1016/j.anaerobe.2011.03.017> PMID:21524712
 20. Jepsen K, Jepsen S. Antibiotics/antimicrobials: systemic and local administration in the therapy of mild to moderately advanced periodontitis. *Periodontology* 2000. 2016; 71(1):82-112. <https://doi.org/10.1111/prd.12121> PMID:27045432
 21. Chiappe V, Gómez M, Fernández-Canigia L, Romanelli H. The effect of spiramycin on *Porphyromonas gingivalis* and other "classic" periopathogens. *Acta Odontol Latinoam.* 2011; 24(1):115-21. PMID:22010417
 22. Rams TE, Slots J. Antibiotics in periodontal therapy: An update. *Compend Contin Educ Dent.* 1992; 13:1130.
 23. Dabija-Wolter G, Al-Zubaydi SS, Mohammed MMA, Bakken V, Bolstad AI. The effect of metronidazole plus amoxicillin or metronidazole plus penicillin V on periodontal pathogens in an in vitro biofilm model. *Clin Exp Dent Res.* 2018; 4(1):6-12. <https://doi.org/10.1002/cre2.96> PMID:29744209 PMID:PMC5813892
 24. Jorgensen MG, Slots J. Practical antimicrobial periodontal therapy. *Compendium of continuing education in dentistry* (Jamesburg, NJ: 1995). 2000; 21(2):111-4.
 25. Prakasam A, Elavarasu SS, Natarajan RK. Antibiotics in the management of aggressive periodontitis. *Journal of pharmacy & bioallied sciences.* 2012; 4(Suppl 2):S252. <https://doi.org/10.4103/0975-7406.100226> PMID:23066264 PMID:PMC3467876
 26. Mombelli A, Almaghlouth A, Cionca N, Cancela J, Courvoisier DS, Giannopoulou C. Microbiologic Response to Periodontal Therapy and Multivariable Prediction of Clinical Outcome. *J Periodontol.* 2017; 88(12):1253-1262. <https://doi.org/10.1902/jop.2017.170286> PMID:28844191
 27. Harks I, Koch R, Eickholz P, Hoffmann T, Kim TS, Kocher T, et al. Is progression of periodontitis relevantly influenced by systemic antibiotics? A clinical randomized trial. *J Clin Periodontol.* 2015; 42(9):832-42. <https://doi.org/10.1111/jcpe.12441> PMID:26250060 PMID:PMC5054899
 28. Mombelli A, Cionca N, Almaghlouth A, Décaillet F, Courvoisier DS, Giannopoulou C. Are there specific benefits of amoxicillin plus metronidazole in *Aggregatibacter actinomycetemcomitans*-associated periodontitis? Double-masked, randomized clinical trial of efficacy and safety. *J Periodontol.* 2013; 84(6):715-24. <https://doi.org/10.1902/jop.2012.120281> PMID:22873656
 29. Akrivopoulou C, Green IM, Donos N, Nair SP, Ready D. *Aggregatibacter actinomycetemcomitans* serotype prevalence and antibiotic resistance in a UK population with periodontitis. *J Glob Antimicrob Resist.* 2017; 10:54-58. <https://doi.org/10.1016/j.jgar.2017.03.011> PMID:28668698
 30. Alamanda M, Denthumdas SK, Wadgave U, Pharne PM, Patil SJ, Kondreddi S, Deshpande P, Koppikar RS. Comparative Evaluation of Ciprofloxacin Levels in GCF and Plasma of Chronic Periodontitis Patients: Quasi Experimental Study. *J Clin Diagn Res.* 2016; 10(6):ZC47-50. <https://doi.org/10.7860/JCDR/2016/18446.7987>
 31. Müller HP, Holderrieth S, Burkhardt U, Höffler U. In vitro antimicrobial susceptibility of oral strains of *Actinobacillus actinomycetemcomitans* to seven antibiotics. *J Clin Periodontol.* 2002; 29(8):736-42. <https://doi.org/10.1034/j.1600-051X.2002.290810.x> PMID:12390570
 32. Eguchi T, Shimizu Y, Furuhashi K, Fukuyama M. Antibacterial activity of new-quinolone and macrolide antibiotics against oral bacteria. *Kansenshogaku Zasshi.* 2002; 76(11):939-45. <https://doi.org/10.11150/kansenshogakuzasshi1970.76.939> PMID:12508477
 33. Reeves BD, Young M, Grieco PA, Suci P. *Aggregatibacter actinomycetemcomitans* biofilm killing by a targeted ciprofloxacin prodrug. *Biofouling.* 2013; 29(8):1005-14. <https://doi.org/10.1080/08927014.2013.823541> PMID:23952779 PMID:PMC3818142
 34. Suci P, Young M. Selective killing of *Aggregatibacter actinomycetemcomitans* by ciprofloxacin during development of a dual species biofilm with *Streptococcus sanguinis*. *Arch Oral Biol.* 2011; 56(10):1055-63. <https://doi.org/10.1016/j.archoralbio.2011.03.013> PMID:21507381
 35. Tezel A, Yucel O, Orbak R, Kara C, Kavrut F, Yagiz H, Sahin T. The gingival crevicular fluid ciprofloxacin level in subjects with gingivitis and periodontitis, and its effects on clinical parameters. *J Periodontol Res.* 2005; 40(5):395-400. <https://doi.org/10.1111/j.1600-0765.2005.00820.x> PMID:16105092
 36. Ciancio SG. Systemic medications: clinical significance in periodontics. *Journal of clinical periodontology.* 2002; 29:14-8. <https://doi.org/10.1034/j.1600-051X.29.s2.3.x>
 37. Cacchillo DA, Walters JD. Effect of ciprofloxacin on killing of *Actinobacillus actinomycetemcomitans* by polymorphonuclear leukocytes. *Antimicrob Agents Chemother.* 2002; 46(6):1980-4. <https://doi.org/10.1128/AAC.46.6.1980-1984.2002> PMID:PMC127222
 38. Froum SJ, Weinberg MA. An Evaluation of Antibiotic Use in Periodontal and Implant Practices. *Int J Periodontics Restorative Dent.* 2015; 35(4):481-7. <https://doi.org/10.11607/prd.2488> PMID:26133137
 39. Oberoi SS, Dhingra C, Sharma G, Sardana D. Antibiotics in dental practice: how justified are we. *Int Dent J.* 2015; 65(1):4-10. <https://doi.org/10.1111/idj.12146> PMID:25510967
 40. Demirbas F, Gjerme PE, Preus HR. Antibiotic prescribing practices among Norwegian dentists. *Acta Odontol Scand.* 2006; 64(6):355-9. <https://doi.org/10.1080/00016350600844394> PMID:17123912
 41. Mainjot A, D'Hoore W, Vanheusden A, Van Nieuwenhuysen JP. Antibiotic prescribing in dental practice in Belgium. *Int Endod J.* 2009; 42(12):1112-7. <https://doi.org/10.1111/j.1365-2591.2009.01642.x> PMID:19912383
 42. Al-Mubarak S, Al-Nowaiser A, Rass MA, Alsuwyyed A, Alghofili A, Al-Mubarak EK, Ho A. Antibiotic prescription and dental practice within Saudi Arabia; the need to reinforce guidelines and implement specialty needs. *J Int Acad Periodontol.* 2004; 6(2):47-55. PMID:15125015
 43. Vessal G, Khabiri A, Mirkhani H, Cookson BD, Askarian M.

Study of antibiotic prescribing among dental practitioners in Shiraz, Islamic Republic of Iran. *East Mediterr Health J.* 2011; 17(10):763-9. <https://doi.org/10.26719/2011.17.10.763> PMID:22256411

44. Kandemir S, Ergül N. Grievances in cases using antibiotics due to orodental problems and assessment of the need for antibiotics. *Int Dent J.* 2000; 50(2):73-7. <https://doi.org/10.1002/j.1875-595X.2000.tb00802.x> PMID:10945185

45. WHO, Antimicrobial resistance: global report on surveillance 2014, Apr 2014. www.who.int/iris/bitstream/handle/10665/112642/9789241564748_eng.pdf